High-Risk Factors and Therapeutic Advances in Ovarian Cancer
10.3971/j.issn.1000-8578.2025.24.1243
- VernacularTitle:卵巢癌的高危因素和治疗研究进展
- Author:
Xiaoyu SHA
1
;
Weiwei ZUO
2
;
Jing GAN
3
;
Yankun LIU
3
Author Information
1. Clinical Medical College of North China University of Science and Technology, Tangshan 063210, China;Department of Molecular Diagnosis, Tangshan People's Hospital, Tangshan 063001, China.
2. Department of Gynecology, Tangshan People's Hospital, 063001, China.
3. Department of Molecular Diagnosis, Tangshan People's Hospital, Tangshan 063001, China;Key Laboratory of Molecular Oncology in Hebei Province, Tangshan 063001, China;Key Laboratory of Precision Medical Testing in Tangshan, Tangshan 063001, China.
- Publication Type:REVIEWS
- Keywords:
Ovarian cancer;
BRCA1/2;
Genetic testing;
PARP inhibitors;
Treatment
- From:
Cancer Research on Prevention and Treatment
2025;52(7):637-644
- CountryChina
- Language:Chinese
-
Abstract:
Among gynecologic malignancies, ovarian cancer is the most lethal, primarily due to its insidious early symptoms, lack of effective screening methods, and high risk of recurrence. It poses substantial challenges to clinical diagnosis and treatment. In recent years, the clinical application of poly ADP-ribose polymerase inhibitors has promoted a comprehensive management model that integrates targeted therapy with conventional treatments. This review, aiming to provide new perspectives and approaches for future research, summarizes the high-risk factors and first-line treatment strategies for ovarian cancer. Further studies should focus on optimizing personalized treatment strategies and exploring novel targeted therapies to improve patient survival outcomes.
